News & insights
Check out our latest updates
Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes-002 project
Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes-002 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK. The Bio-Hermes-002 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims...
New partnership with the University of Essex to strengthen CANTAB® normative data offering
We’ve joined forces with ESSEXLab at the Centre for Behavioural Science (CBS), University of Essex, to gather normative data from latency-based and rater-scored tasks like our Reaction Time (RTI) task and Verbal Recognition Memory (VRM). This partnership will significantly enrich our normative offerings further and provide robust benchmarks, demonstrating the...
Cambridge Cognition and The Michael J. Fox Foundation to employ digital cognitive assessments in unraveling the mysteries of Parkinson’s disease
Cambridge, UK – 30 April 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessment, has announced that The Michael J. Fox Foundation for Parkinson’s Disease Research will incorporate its CANTAB® cognitive assessments into the Parkinson’s Progression Markers Initiative (PPMI). The landmark initiative will use Cambridge Cognition’s...
Supporting research into central nervous system (CNS) disorders to improve patient quality of life
by Martina De LilloClinical ScientistCambridge Cognition Disorders of the Central Nervous System (CNS) affect billions of people worldwide (The Lancet Neurology, 2022), representing an important cause of death and disability around the world. Life expectancy has been extended in the last years which has increased the number of brain pathologies...
Cambridge Cognition spin-out Monument Therapeutics accesses £1.5m for schizophrenia clinical development
Cambridge, UK – 23 April 2024: Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Monument Therapeutics Limited (“Monument”) a precision neuroscience company spun-out from, and partly owned by Cambridge Cognition, has completed a £1.0 million fundraise and announced...
